145 related articles for article (PubMed ID: 18217197)
1. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis.
Saito E; Koike T; Hashimoto H; Miyasaka N; Ikeda Y; Hara M; Yamada H; Yoshida T; Harigai M; Ichikawa Y
Mod Rheumatol; 2008; 18(1):34-44. PubMed ID: 18217197
[TBL] [Abstract][Full Text] [Related]
2. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients.
Marie I; Menard JF; Hatron PY; Hachulla E; Mouthon L; Tiev K; Ducrotte P; Cherin P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1748-55. PubMed ID: 20722047
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis.
Hara M; Kinoshita M; Saito E; Hashimoto H; Miyasaka N; Yoshida T; Ichikawa Y; Koike T; Ichikawa Y; Okada J; Kashiwazaki S
Mod Rheumatol; 2003 Dec; 13(4):319-25. PubMed ID: 24387253
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial.
Miyasaka N; Hara M; Koike T; Saito E; Yamada M; Tanaka Y;
Mod Rheumatol; 2012 Jun; 22(3):382-93. PubMed ID: 21971943
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin therapy for refractory myositis.
Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
Intern Med; 1996 Aug; 35(8):663-7. PubMed ID: 8894745
[TBL] [Abstract][Full Text] [Related]
9. [Intravenous immunoglobulins in polymyositis and dermatomyositis].
Chérin P; Herson S
Rev Med Interne; 1999; 20 Suppl 4():436s-439s. PubMed ID: 10522319
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis.
Galimberti F; Kooistra L; Li Y; Chatterjee S; Fernandez AP
Clin Exp Dermatol; 2018 Dec; 43(8):906-912. PubMed ID: 29856076
[TBL] [Abstract][Full Text] [Related]
11. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
12. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
Chérin P; Herson S
Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
[TBL] [Abstract][Full Text] [Related]
13. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis.
Xiong A; Qiang Y; Cao Y; Shuai Y; Chen H; Xiang Q; Hu Z; Song Z; Zhou S; Zhang Y; Cui H; Wang Y; Luo J; Shuai S; Yang Y
Mod Rheumatol; 2023 Apr; 33(3):533-542. PubMed ID: 35660927
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
[TBL] [Abstract][Full Text] [Related]
17. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
[TBL] [Abstract][Full Text] [Related]
18. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
[TBL] [Abstract][Full Text] [Related]
19. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis.
Marie I; Hachulla E; Levesque H; Reumont G; Ducrotte P; Cailleux N; Hatron PY; Devulder B; Courtois H
J Rheumatol; 1999 Dec; 26(12):2706-9. PubMed ID: 10606390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
